Monoclonal Antibody Shows Promise in Stopping ARDS Cytokine Storm

By Debbie Bunch

July 13, 2026 | 2 min read

A small proof-of-concept study conducted at U.S. medical centers offers hope that a treatment may one day be available to curtail the inflammatory condition known as the cytokine storm that often devastates people with acute respiratory distress syndrome (ARDS). The trial randomized 15 patients to …

This content is for AARC members only.

Become a Member

Read Abstract Read Article

Debbie Bunch

Debbie Bunch has a bachelor's degree in journalism from the University of North Texas and lives in Dallas, Texas. She has spent many years writing for the AARC on topics ranging from clinical innovations to management. In her spare time, she enjoys traveling, reading, photography, and spending time with friends, family, and her rescue pup Juju.

Share